Intellipharmaceutics International Inc. (IPCI)

[fred198484]

I believe you have it about right. This is the most likely outcome. IF it is not a CRL, then it is a positive for the company and the stock as the company then has a significant product on the horizon. If Rexista is dead in the water, however, it is going to be a long time before PODRAS or Regbatin are on the radar screen and we will only have generics between now and then. That is not very exciting. So, I am hoping the FDA gives Rexista a pathway to approval and I think that is the most likely outcome. Rexista remains the best alternative in the space and the FDA knows that.